Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF K601E MAP2K1 V211D |
Therapy | MAP855 |
Indication/Tumor Type | colon cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF K601E MAP2K1 V211D | colon cancer | sensitive | MAP855 | Preclinical - Pdx | Actionable | In a preclinical study, MAP855 inhibited Rsk and Erk phosphorylation, and resulted in 30% tumor regression in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518). | 31227518 |
PubMed Id | Reference Title | Details |
---|---|---|
(31227518) | V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. | Full reference... |